Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

Why a $34 Million Teva Stock Position Signals Confidence in a Long Repair Story

Why a $34 Million Teva Stock Position Signals Confidence in a Long Repair Story ↗

December 27, 2025

S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive

Topics Regulatory Compliance

December 24, 2025

Billionaire Stanley Druckenmiller Sold Nvidia and Palantir and Piled Into One of Wall Street's Hottest Drug Stocks Ahead of 2026 ↗

December 24, 2025

Duquesne Family Office's billionaire boss has jettisoned the faces of the artificial intelligence (AI) revolution in favor of a drugmaker whose shares have rallied 191% since the beginning of 2024.

According to the settlement agreement, the proposed biosimilar to Eylea® (aflibercept) can be marketed in the U.S., if approved by the FDA, in the fourth quarter of 2026, or earlier under certain...

Topics Artificial Intelligence

Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®

December 19, 2025

This combination of growth and value stocks has the tools and intangibles necessary to outperform in the year to come.

My Top 10 Portfolio Holdings for 2026 ↗

December 19, 2025

Teva Pharmaceutical is more complex than you may realize, even though that's part of the company's plan.

Topics Stocks

3 Things You Need to Know if You Buy Teva Pharmaceutical Stock Today ↗

December 17, 2025

Teva Pharmaceutical is a leader in generic drugs, but these struggling makers of branded drugs may be a better choice.

Topics Intellectual Property

Should You Forget Teva Pharmaceutical and Buy These Unstoppable Stocks Instead? ↗

December 14, 2025

Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026

Topics Intellectual Property

December 12, 2025

Teva Releases Q4 2025 Aide Memoire

December 12, 2025

Glenview Capital Management reduced its stake in Alight by roughly 16% during the third quarter.

Glenview Capital Management Sells $71 Million of Alight Stake After Stock's 71% Drop ↗

December 09, 2025

Glenview Doubles Down on Teva Stock With $72 Million Buy, According to Recent SEC Filing ↗

Topics Regulatory Compliance

December 09, 2025

Glenview Capital Management added to its massive position in Teva Pharmaceuticals stock.

Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

Topics Regulatory Compliance

December 09, 2025

The global prescription drugs market is on the cusp of a significant expansion, with recent market reviews and forecasts projecting a robust growth trajectory through 2035. This anticipated surge,...

Global Prescription Drug Market Poised for Trillion-Dollar Surge by 2035

December 03, 2025

Via MarketMinute

Topics Artificial Intelligence Death Intellectual Property

30% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 3 Biotech Stocks ↗

November 30, 2025

Stanley Druckenmiller is considered one of the greatest investors of all time.

Biotech Bull ETF Surges To 20-Month High: Analysts Say Medicare’s Drug-Pricing Blow Is Softer Than Feared ↗

Topics Artificial Intelligence

November 27, 2025

Pricing updates for major therapies from Novo Nordisk, Teva, AbbVie, and others eased sector worries.

Via Stocktwits

Topics ETFs

JPMorgan Says 2027 Medicare Drug Prices Signal Up To 40% Cuts Ahead — Novo Nordisk And Teva Stand Out As Top Targets ↗

November 26, 2025

JPMorgan said the implied net impact aligns with recent commentary from Novo Nordisk, Teva and AbbVie during earnings season.

Via Stocktwits

Topics Economy Government

Medicare Slashes Ozempic's Price Tag 71%; Why Novo Nordisk Rallied ↗

November 26, 2025

Novo Nordisk stock jumped Wednesday on a lighter-than-feared discount for Ozempic and Wegovy under the IRA.

Via Investor's Business Daily

Topics Economy Government

Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®

November 25, 2025

Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi’s 2025 Global Healthcare Conference in December

November 21, 2025

Jury convicts Done Global founder Ruthia He and former top doctor David Brody in a federal case alleging illegal Adderall distribution through the telehealth platform.

Jury Convicts Done Global Founder In Adderall Distribution Scheme: WSJ Report ↗

November 19, 2025

Via Benzinga

Topics Law Enforcement

Teva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufacturing, Digital Health and Biotech Breakthroughs for Pharma’s Biggest Challenges

November 19, 2025

Druckenmiller Opens Position In Amazon, Closes Microsoft — Here's More Of Duquesne's Biggest Q3 Moves ↗

November 14, 2025

Stanley Druckenmiller's Duquesne Family Office Q3 13F reinforces the firm's reputation for agile and opportunity-driven asset allocation.

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 11, 2025

Via Benzinga

Billionaire Stanley Druckenmiller Sold His Fund's Entire Stakes in Nvidia and Palantir for a Scorching-Hot Drug Stock That's Up 218% Since Mid-2023 ↗

November 11, 2025

Duquesne Family Office's billionaire boss has gone full contrarian by selling Wall Street's two artificial intelligence (AI) darlings and piling into a previously struggling pharmaceutical stock.

Here's How Much $100 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth Today ↗

Topics Artificial Intelligence

November 10, 2025

Via Benzinga

Price Over Earnings Overview: Teva Pharmaceutical Indus ↗

November 10, 2025

Via Benzinga

Expedia, Sandisk and Penumbra Are Among the Top 10 Large-Cap Gainers Last Week (Nov. 3-Nov. 7): Are the Others in Your Portfolio? ↗

November 09, 2025

Expedia, SanDisk, and Penumbra led last week's large-cap gainers, with strong earnings and raised guidance fueling broad double-digit jumps.

Via Benzinga

AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living

November 07, 2025

The company delivered a convincing pair of beats in its third-quarter earnings report.

Why Teva Pharmaceutical Stock Rocked the Market Today ↗

November 05, 2025